We apologize your item could not be found. Not all items are listed on our website. Please contact your account manager for details regarding your searched item.
Material number (eg: xxxxxxxxxxx) no space or hyphen needed.
No Results Found
Pharmaceutical drug development and commercial manufacturing is complex and risky. Packaging and drug delivery add challenges. With West by your side, you can find solutions to industry challenges such as:
Injectable medicines are taken by millions of people day in and day out to treat a variety of chronic illnesses such as arthritis, Crohn’s disease, diabetes, osteoporosis, multiple sclerosis, and others. Oftentimes, these treatments may involve patients self-injecting, which can be far more convenient than having to visit a doctor’s office, but can also be intimidating.1 For patients who need to self-inject, anxiety around the process is a reality for 25% of adults and for 63% of younger people. This anxiety is not only unpleasant, it can also lead to a lack of adherence with prescribed medications, which can result in poor outcomes.2
Scale‑up should be intentional, not reactive. Manufacturing systems that support clinical supply must also be evaluated for commercial readiness.
You’re the one who has to say “yes” with confidence.
Not a vague yes. Not a hopeful yes. A regulatory-grade yes - supported by evidence, traceability, risk rationale, and a documentation trail that can withstand scrutiny years after the decision was made.
And the hard part is: you’re asked to deliver that certainty while everything around you is still moving. Formulation evolves. Device choices shift. Timelines compress. Stakeholders push. Yet your role stays the same: protect the approval path and, ultimately, patient safety.
Injectable medicines are taken by millions of people day in and day out to treat a variety of chronic illnesses such as arthritis, Crohn’s disease, diabetes, osteoporosis, multiple sclerosis, and others. Oftentimes, these treatments may involve patients self-injecting, which can be far more convenient than having to visit a doctor’s office, but can also be intimidating.1 For patients who need to self-inject, anxiety around the process is a reality for 25% of adults and for 63% of younger people. This anxiety is not only unpleasant, it can also lead to a lack of adherence with prescribed medications, which can result in poor outcomes.2
Scale‑up should be intentional, not reactive. Manufacturing systems that support clinical supply must also be evaluated for commercial readiness.
You’re the one who has to say “yes” with confidence.
Not a vague yes. Not a hopeful yes. A regulatory-grade yes - supported by evidence, traceability, risk rationale, and a documentation trail that can withstand scrutiny years after the decision was made.
And the hard part is: you’re asked to deliver that certainty while everything around you is still moving. Formulation evolves. Device choices shift. Timelines compress. Stakeholders push. Yet your role stays the same: protect the approval path and, ultimately, patient safety.
English
Chinese
